NewBiologix

Executive Summary

NewBiologix is a private biotechnology company headquartered in Research Triangle Park, NC, dedicated to developing advanced gene therapies for rare genetic diseases. Founded in 2020, the company employs 50-200 people and has raised $50 million in funding. Its platform leverages novel genetic engineering and delivery technologies to achieve precise genomic correction for monogenic disorders with high unmet medical need. The company is currently in the Phase 1 stage, with its pipeline targeting conditions that lack effective treatments. By focusing on validated genetic targets and proprietary delivery systems, NewBiologix aims to offer durable, one-time curative therapies for patients. The company's scientific approach combines cutting-edge CRISPR-based editing with next-generation viral vectors to enhance specificity and safety. With a strong intellectual property portfolio and experienced management team, NewBiologix is poised to advance its lead programs into clinical development. The company's progress will be closely watched by investors and the rare disease community, as its therapies hold potential to transform the standard of care for several devastating genetic disorders.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 trial initiation for lead candidate NBX-10170% success
• Q4 2026Series B financing round80% success
• Q2 2026Orphan Drug Designation from FDA for lead program85% success